These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Treatment of the acute migraine attack]. Titus F Rev Neurol; 1995; 23 Suppl 2():S203-7. PubMed ID: 7497289 [No Abstract] [Full Text] [Related]
4. [The treatment of migraine]. Titus F Rev Neurol; 1997 Feb; 25(138):295-300. PubMed ID: 9147762 [No Abstract] [Full Text] [Related]
5. An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Villalón CM; Centurión D; Valdivia LF; De Vries P; Saxena PR Proc West Pharmacol Soc; 2002; 45():199-210. PubMed ID: 12434581 [TBL] [Abstract][Full Text] [Related]
6. Ergotamine, dihydroergotamine: current uses and problems. Tfelt-Hansen P Curr Med Res Opin; 2001; 17 Suppl 1():s30-4. PubMed ID: 12463275 [TBL] [Abstract][Full Text] [Related]
10. [Serotonin agonists and antagonists in migraine]. Ollat H Pathol Biol (Paris); 1992 Apr; 40(4):389-96. PubMed ID: 1353874 [TBL] [Abstract][Full Text] [Related]
11. The way to serotonergic use and abuse in migraine. Nicolodi M; Del Bianco PL; Sicuteri F Int J Clin Pharmacol Res; 1997; 17(2-3):79-84. PubMed ID: 9403359 [TBL] [Abstract][Full Text] [Related]
12. The pharmacology of ergotamine and dihydroergotamine. Silberstein SD Headache; 1997; 37 Suppl 1():S15-25. PubMed ID: 9009470 [TBL] [Abstract][Full Text] [Related]
13. [Improper equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System]. Ferrari MD; Haan J; Bax WA; van Coevorden RS; Timmerman H; Meijler WJ Ned Tijdschr Geneeskd; 1993 Apr; 137(17):846-50. PubMed ID: 8387648 [No Abstract] [Full Text] [Related]
14. [Unjustified equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System]. Van Mil JW Ned Tijdschr Geneeskd; 1993 Jun; 137(24):1213-4. PubMed ID: 8391659 [No Abstract] [Full Text] [Related]
15. Sumatriptan fast-disintegrating/rapid-release tablets in the acute treatment of migraine. Barbanti P; Le Pera D; Cruccu G Expert Rev Neurother; 2007 Aug; 7(8):927-34. PubMed ID: 17678486 [TBL] [Abstract][Full Text] [Related]
16. The 5-HT Whealy M; Becker WJ Handb Clin Neurol; 2024; 199():17-42. PubMed ID: 38307644 [TBL] [Abstract][Full Text] [Related]
17. [Migraine: selection of therapeutic agents to be applied during its attack]. Yamane K Nihon Naika Gakkai Zasshi; 2001 Apr; 90(4):601-6. PubMed ID: 11391906 [No Abstract] [Full Text] [Related]
18. Coronary side-effect potential of current and prospective antimigraine drugs. MaassenVanDenBrink A; Reekers M; Bax WA; Ferrari MD; Saxena PR Circulation; 1998 Jul; 98(1):25-30. PubMed ID: 9665056 [TBL] [Abstract][Full Text] [Related]
19. [Emergency treatment of migraine attacks with particular reference to agonists of 5-HT1B/1D receptor]. Prusiński A Neurol Neurochir Pol; 1999; 32 Suppl 6():39-49. PubMed ID: 11107563 [TBL] [Abstract][Full Text] [Related]
20. Acute and prophylactic treatment of migraine: practical approaches and pharmacologic rationale. Raskin NH Neurology; 1993 Jun; 43(6 Suppl 3):S39-42. PubMed ID: 8389010 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]